Five Prime Therapeutics (NASDAQ: FPRX) is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008 in phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor; and phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. For more information, visit the company’s website at www.fiveprime.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
